SARASOTA, Fla., June 23, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...

Currently, it is estimated that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treatedSARASOTA, Fla., June 19, 2020 -- Today, Steve Shum, Chief Executive Officer of INVO Bioscience, Inc. (OTCQB: INVO) (OTCQB: INVOD), a...

SARASOTA, Fla., May 22, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System,...

Company to Participate in Virtual Investor Conference on May 20 at 2:00pm ET (Details Below)SARASOTA, Fla., May 15, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility...

SARASOTA, Fla., April 2, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on treating infertility with its FDA-cleared INVOcell® product, announced today the appointment of Christopher A. Myer as Vice President Business Development -...

SARASOTA, Fla., March 30, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System,...

INVO's novel, FDA-cleared INVOcell technology provides an in-vivo incubation solution which can help increase access and capacity to the large underserved global fertility marketSARASOTA, Fla., March 16, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO) ("INVO"), a medical...